Stock exchanges & markets

Overview Watchlists

Addex Therapeutics appoints Jean-Philippe Rocher head of pharmaceutical development

2. Oct 2026

(AWP Alliance News) - Addex Therapeutics appointed Jean-Philippe Rocher as head of pharmaceutical development, adding him to executive management. Rocher returns from Neurosterix, where he served as head of pharmaceutical development following its 2024 spin-out from Addex.

He previously held roles including CNS program director at Pierre Fabre, director of chemistry at Devgen, and senior research scientist at GlaxoSmithKline KK. Separately, Mikhail Kalinichev stepped down as head of translational science to focus on a similar role at Neurosterix.

http://www.globenewswire.com/newsroom/news.html?d=1001275845

Disclaimer: This news brief was created using generative artificial intelligence. Addex Therapeutics Ltd. published the original content used to generate this news brief via GlobeNewswire on October 02, 2026, and is solely responsible for the information contained therein.

Learn more about our offers

  • Keep a close eye on your favourite shares

    Watchlist

    Don’t miss out on share price trends. Track your favourite shares (CH, EU & US) in real time with customised watchlists.

    Sign up now

  • Compare ETFs systematically

    ETF Compass

    Find the products that suit your investment goals.

    Try the ETF Compass

  • How to find the best shares

    theScreener

    Search through around 6,500 securities using criteria such as opportunities and risks or expected dividend yield.

    Test now